INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS)
New results characterizing the molecular signature of Epstein-Barr Virus (EBV) in MS brain lesions will also be presented Presentations to take place during the upcoming MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
View HTML
Toggle Summary Atara Biotherapeutics to Present at Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the Company will present at three upcoming investor conferences in June: Jefferies 2017 Global Healthcare Conference Isaac Ciechanover, M.D., the Company's President and
View HTML
Toggle Summary Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that the compensation committee of Atara's board of directors, approved a grant, effective as of May 10, 2017, to Dr. Derrell Porter in connection with his employment at the
View HTML
Toggle Summary Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team
SOUTH SAN FRANCISCO, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced the appointment of Dr. Derrell Porter as Senior Vice President and Global Commercial Head. Dr. Porter brings extensive commercialization experience to the management team as Atara
View HTML
Toggle Summary Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today reported financial results for the first quarter of 2017 and recent operational highlights. "We continued to make important progress advancing our robust pipeline of T-cell therapies in the
View HTML
Toggle Summary Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
SOUTH SAN FRANCISCO, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has entered into a clinical trial
View HTML
Toggle Summary Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
Encouraging Clinical Improvements Correlate with EBV Reactivity   Presentation Selected for Emerging Science and Conference Press Programs by AAN SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on
View HTML
Toggle Summary Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
SOUTH SAN FRANCISCO, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that it
View HTML
Toggle Summary Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
Presentation Selected for the Emerging Science Program at the American Academy of Neurology (AAN) Annual Meeting 2017
View HTML
Toggle Summary Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial
View HTML